As of 2024-12-12, the Intrinsic Value of Rigel Pharmaceuticals Inc (RIGL) is
1.10 USD. This RIGL valuation is based on the model Peter Lynch Fair Value.
With the current market price of 19.53 USD, the upside of Rigel Pharmaceuticals Inc is
-94.36%.
RIGL Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(96.78) - (31.54) |
(46.93) |
-340.3% |
| DCF (Growth 10y) |
(38.38) - (110.61) |
(55.53) |
-384.3% |
| DCF (EBITDA 5y) |
(25.52) - (32.55) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(35.17) - (46.84) |
(1,234.50) |
-123450.0% |
| Fair Value |
1.10 - 1.10 |
1.10 |
-94.36% |
| P/E |
4.03 - 7.64 |
5.28 |
-73.0% |
| EV/EBITDA |
5.95 - 9.94 |
6.66 |
-65.9% |
| EPV |
(15.21) - (19.82) |
(17.52) |
-189.7% |
| DDM - Stable |
2.72 - 12.36 |
7.54 |
-61.4% |
| DDM - Multi |
(26.66) - (93.83) |
(41.49) |
-312.4% |
RIGL Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
344.12 |
| Beta |
2.69 |
| Outstanding shares (mil) |
17.62 |
| Enterprise Value (mil) |
352.19 |
| Market risk premium |
4.60% |
| Cost of Equity |
7.63% |
| Cost of Debt |
13.70% |
| WACC |
7.92% |